Equities
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)324.40
  • Today's Change0.600 / 0.19%
  • Shares traded127.82k
  • 1 Year change+11.55%
  • Beta0.7104
Data delayed at least 15 minutes, as of Jul 18 2025 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

  • Revenue in SEK (TTM)1.06bn
  • Net income in SEK147.98m
  • Incorporated2010
  • Employees140.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Swedencare AB (publ)2.59bn92.70m7.54bn552.0080.781.0318.352.910.58370.583716.2945.820.25953.519.084,618,750.000.92991.160.96591.2036.5236.003.584.402.503.370.192844.568.6282.0968.7727.0269.3912.30
BioGaia AB1.42bn309.74m10.64bn224.0035.246.1432.197.503.063.0614.0417.590.629----6,307,498.0013.7314.7614.9016.0372.8173.0621.8327.38----0.00129.549.7313.11-3.8213.40-18.3633.95
Bonesupport Holding AB1.06bn147.98m21.33bn140.00145.2727.13134.6120.072.232.2315.9711.931.240.6045.628,366,000.0017.255.1420.536.3192.5991.4013.935.593.5114.830.01570.0052.0542.04-45.41--5.71--
Bavarian Nordic A/S9.45bn2.00bn21.81bn1.65k11.011.237.212.3116.5716.5778.33148.460.45861.416.753,867,985.009.723.3111.784.0251.9052.6821.209.801.44--0.010.00-19.0653.88-33.03---8.77--
Vimian Group AB4.42bn218.02m22.73bn1.20k103.522.9136.625.150.41760.41768.4814.880.3751.766.483,680,164.001.96--2.20--69.01--5.23--1.224.870.2423--12.95--88.01------
Camurus AB2.04bn547.78m41.40bn265.0075.7711.7273.3420.349.169.1634.0759.220.57921.095.027,952,883.0015.588.6517.4410.4693.2391.3126.9112.019.10--0.02970.008.7877.63-0.7065--1.29--
ALK-Abello A/S8.65bn1.42bn59.57bn2.74k45.367.5732.376.884.284.2826.0825.620.76251.266.442,073,375.0012.526.0115.297.6064.4561.9516.428.440.987557.350.12350.0014.7811.0867.70--50.82--
Swedish Orphan Biovitrum AB (publ)26.97bn4.37bn97.62bn1.94k21.772.4212.103.6212.6012.6077.70113.350.38011.455.2814,657,070.006.155.237.676.7078.4877.7016.1815.190.65536.230.2470.0017.6512.8161.273.29-20.97--
Orion Oyj17.97bn3.93bn105.34bn3.94k26.758.7123.575.862.472.4711.297.581.001.526.24409,407.2021.9620.1428.9324.6761.5459.7221.8621.162.27125.290.231484.2529.657.9752.1710.4819.141.80
Data as of Jul 18 2025. Currency figures normalised to Bonesupport Holding AB's reporting currency: Swedish Krona SEK

Institutional shareholders

34.86%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 30 May 20256.46m9.81%
Capital Research & Management Co. (World Investors)as of 31 Mar 20255.01m7.60%
Handelsbanken Fonder ABas of 30 Jun 20252.56m3.88%
The Vanguard Group, Inc.as of 02 Jul 20252.30m3.50%
SEB Investment Management ABas of 30 Jun 20251.53m2.32%
Norges Bank Investment Managementas of 31 Dec 20241.48m2.24%
DNCA Finance SAas of 30 Jun 20241.03m1.57%
JPMorgan Asset Management (UK) Ltd.as of 31 May 2025937.68k1.42%
SEB Investment Management AB (Denmark)as of 30 Jun 2025833.64k1.27%
BlackRock Fund Advisorsas of 03 Jul 2025825.49k1.25%
More ▼
Data from 31 Dec 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.